| Literature DB >> 27433285 |
Farzana Ganjifrockwala1, Jim Joseph1, Grace George1.
Abstract
Oxidized low-density lipoprotein (ox-LDL) is a powerful natural prooxidant derived from native LDL by cell-mediated oxidation. Such oxidation occurs more easily in glycated LDL as observed in diabetes mellitus. We evaluated and compared selected biomarkers of oxidative stress and total antioxidant (TAO) levels in type 2 diabetes mellitus (T2DM) patients with and without retinopathy in the Mthatha region of the Eastern Cape Province, South Africa. The participants totaled to 140 and this number comprised 98 diabetic patients on treatment, stratified by diabetes (54) and diabetes with retinopathy (44). Forty-two nondiabetic healthy controls made up the 140. Fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), lipid profile, serum ox-LDL, thiobarbituric acid reactive substances (TBARS), and TAO levels were measured. A statistically significant increase in FPG, HbA1c, TBARS, and ox-LDL and a significant decrease in TAO levels were seen in T2DM patients with retinopathy as compared to controls. A significant negative correlation was observed between TAO and ox-LDL levels in the diabetic group. In multiple linear regression analyses, duration of diabetes, triglyceride, TAO, and LDL cholesterol were found to be significantly associated with ox-LDL. In multiple logistic regression analyses, ox-LDL [OR 1.02 (1.01-1.03), P = 0.005] was the only risk factor and was significantly associated with the presence of retinopathy.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27433285 PMCID: PMC4940560 DOI: 10.1155/2016/2063103
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Profile of research participants in different groups.
| Variables | Groups | |||
|---|---|---|---|---|
| Control (nondiabetic) | Diabetic without retinopathy | DR | Total% | |
| Gender | ||||
| Female |
|
|
| 62.1% |
| Male |
|
|
| 37.9% |
| Hypertension | N/A |
|
| 74.5% |
| Physical activity |
|
|
| 58.6% |
| Alcohol consumption |
|
|
| 7.9% |
| Smoking |
|
|
| 8.6% |
| Family history | N/A |
|
| 57.1% |
| Medication | ||||
| Oral drugs | N/A |
|
| 70.4% |
| Insulin | N/A |
|
| 29.6% |
DR: diabetic retinopathy.
Mean age, duration of diabetes, and anthropometric data in different groups.
| Variables | Groups | |||
|---|---|---|---|---|
| Control (nondiabetic) | Diabetic without retinopathy | DR |
| |
| Age (years) | 54.67 ± 6.76 | 56.50 ± 7.56 | 58.52 ± 8.66 | 0.071 |
| Duration of diabetes (years) | N/A | 5.0 (8.25–2.0) | 10.0 (15.0–5.0) | <0.0005 |
| BMI (Kg/m2) | 29.7 (35.1–25.2) | 31.3 (36.6–26.0) | 31.7 (35.7–26.2) | 0.618 |
| Weight (Kg) | 77.0 (87.5–65.8) | 80.0 (95.2–69.5) | 80.0 (92.7–69.2) | 0.331 |
| Height (cm) | 160.0 (163.5–155.5) | 162.0 (168.5–155) | 160.0 (165–155) | 0.249 |
| Waist circumference (cm) | 97.5 (106–80.5) | 99.0 (109–91) | 100.0 (108.5–91) | 0.135 |
| Hip circumference (cm) | 107.5 (122–93.8) | 106.5 (118.2–99) | 105.5 (116–99.5) | 0.859 |
| Waist/hip ratio | 0.87 (0.89–0.85) | 0.91 (0.94–0.87) | 0.93 (0.95–0.89) | <0.0005 |
Data is shown as mean ± SD (standard deviation) and median and IQR (interquartile range). The mean and median difference is significant at P < 0.0005 level. DR: diabetic retinopathy.
Clinical characteristics in different groups.
| Variables | Groups | |||
|---|---|---|---|---|
| Control (nondiabetic) | Diabetic without retinopathy | DR |
| |
| FPG (mmol/L) | 4.9 (5.2–4.6) | 8.1 (10.5–6.3) | 9.6 (13.1–6.5) | <0.0005 |
| HbA1c (%) | 6.0 (6.1–5.8) | 8.1 (10.2–6.8) | 9.0 (11.1–8.0) | <0.0005 |
| Total cholesterol (mmol/L) | 4.80 (5.37–3.87) | 4.50 (5.05–3.67) | 4.55 (5.37–3.83) | 0.438 |
| LDL cholesterol (mmol/L) | 2.75 ± 0.88 | 2.51 ± 0.96 | 2.65 ± 1.01 | 0.490 |
| HDL cholesterol (mmol/L) | 1.35 (1.52–1.10) | 1.11 (1.40–1.0) | 1.18 (1.36–0.91) | 0.007 |
| Triglyceride (mmol/L) | 1.10 (1.52–0.90) | 1.30 (2.0–1.0) | 1.50 (2.54–1.11) | 0.004 |
| Total antioxidant (mM) | 0.60 (0.80–0.44) | 0.47 (0.61–0.37) | 0.34 (0.45–0.23) | <0.0005 |
| TBARS ( | 3.38 (4.62–2.32) | 4.33 (6.0–3.3) | 5.08 (6.12–4.0) | <0.0005 |
| Serum oxidized LDL (U/L) | 81.76 ± 31.74 | 97.52 ± 40.67 | 146.9 ± 56.67 | <0.0005 |
Data is shown as median and IQR (interquartile range) and mean ± SD. The median and mean difference is significant at P < 0.05, P < 0.005, and P < 0.0005 level. DR: diabetic retinopathy.
Spearman's correlation coefficients between lipid parameters, FPG, HbA1c, TBARS, and ox-LDL in all groups.
| Groups | TC | LDL-C | HDL-C | Triglyceride | FPG | HbA1c | TBARS |
|---|---|---|---|---|---|---|---|
| ox-LDL in control group | 0.279 | 0.470 | −0.593 | 0.179 | 0.198 | 0.309 | −0.469 |
| ox-LDL in diabetic group | 0.424 | 0.417 | −0.002 | 0.293 | 0.053 | 0.040 | 0.134 |
Data is presented as Spearman correlation coefficient (r), P < 0.05. TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; FPG: fasting plasma glucose; HbA1c: glycosylated hemoglobin; ox-LDL: oxidized LDL.
Figure 1Correlation between TAO and ox-LDL in diabetic group (diabetics with and without retinopathy). Values were considered statistically significant when P < 0.05.
Figure 2Correlation between LDL cholesterol and ox-LDL in diabetic group (diabetics with and without retinopathy). Values were considered statistically significant when P < 0.05.
Multiple linear regression analyses showing relationship between ox-LDL and various parameters.
| Model |
| SE | Beta |
|
|---|---|---|---|---|
| 1 (constant) | −91.539 | 104.241 | 0.383 | |
| Age | .906 | .630 | .140 | 0.155 |
| BMI | 1.123 | .747 | .152 | 0.137 |
| DD | 2.170 | .914 | .244 | 0.020 |
| FPG | .880 | 1.458 | .070 | 0.548 |
| HbA1c | −1.921 | 2.501 | −.092 | 0.445 |
| TAO | −58.877 | 26.105 | −.225 | 0.027 |
| TBARS | .015 | 2.548 | .001 | 0.995 |
| WHR | 76.139 | 77.907 | .092 | 0.332 |
| TG | 16.962 | 6.593 | .273 | 0.012 |
| HDL-C | −1.480 | 20.097 | −.008 | 0.941 |
| LDL-C | 17.692 | 5.310 | .327 | 0.001 |
B (SE): unstandardized regression coefficient with standard error; Beta: standardized regression coefficient.
BMI: body mass index; DD: duration of diabetes; FPG: fasting plasma glucose; HbA1c: glycosylated hemoglobin; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TAO: total antioxidant; ox-LDL: oxidized LDL; TBARS: thiobarbituric acid reactive substances; WHR: waist/hip ratio; TG: triglycerides. P < 0.05.
Independent markers associated with diabetic retinopathy among diabetic patients and using multiple logistic regression analysis.
|
| SE | Wald | Sig. | Exp ( | 95% CI for Exp ( | |||
|---|---|---|---|---|---|---|---|---|
| Lower | Upper | |||||||
| Step 1a | Age | .019 | .034 | .319 | .572 | 1.020 | .953 | 1.091 |
| HbA1c | .181 | .116 | 2.460 | .117 | 1.199 | .956 | 1.504 | |
| DD | .092 | .055 | 2.783 | .095 | 1.096 | .984 | 1.222 | |
| TG | .076 | .322 | .056 | .813 | 1.079 | .574 | 2.030 | |
| HDL-C | –.728 | 1.095 | .442 | .506 | .483 | .056 | 4.131 | |
| TAO | –1.840 | 1.423 | 1.672 | .196 | .159 | .010 | 2.584 | |
| Ox-LDL | .018 | .006 | 7.861 | .005 | 1.018 | 1.005 | 1.030 | |
| TBARS | –.010 | .131 | .006 | .936 | .990 | .766 | 1.279 | |
| Constant | –4.055 | 3.006 | 1.820 | .177 | .017 | |||
aVariable(s) entered on step 1: age, HbA1c, DD, TG, HDL, TAO, ox-LDL, and TBARS.
DD: duration of diabetes; HbA1c: glycosylated hemoglobin; TG: triglycerides; HDL-C: high-density lipoprotein cholesterol; TAO: total antioxidant; ox-LDL: oxidized LDL; TBARS: thiobarbituric acid reactive substances. P < 0.05.
Figure 3ROC curve for ox-LDL in diabetic groups.